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Edited by Masayuki MiyasakaAbstract The monoglucosylated oligomannose N-linked oligo-
saccharide (Glc1Man9GlcNAc2) is a retention signal for the
calnexin–calreticulin quality control pathway in the endoplasmic
reticulum. We report here the presence of such monoglucosylated
N-glycans on the human complement serum glycoprotein C3.
This ﬁnding represents the ﬁrst report of monoglucosylated
glycans on a human serum glycoprotein from non-diseased
individuals. The presence of the glucose moiety in 5% of the
human C3 glycoprotein suggests that this glycosylation site is
sequestered within the protein and is consistent with previous
studies identifying a cryptic conglutinin binding site on C3 that
becomes exposed upon its conversion to iC3b.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The endoplasmic reticulum (ER) folding pathway is an an-
cient and highly regulated quality control system for protein
biosynthesis [1]. It is notable for both its degree of conserva-
tion in eukaryotes and its eﬃciency in preventing the exit of
misfolded proteins from the ER. Glycosylation has a critical
role in protein folding and is consequently required for the
eﬃcient secretion of serum glycoproteins [1]. N-linked glyco-
sylation occurs co-translationally by the transfer of
Glc3Man9GlcNAc2 to the side chain of asparagine found
within the glycosylation sequon N-X-S/T (where X is not
proline) of the nascent polypeptide [2]. The Glca1-2Glca1-
3Glca1-3 moiety is fully hydrolysed from proteins that exit the
ER [1]. Monoglucosylation is the recognition signal for the
chaperones calnexin and calreticulin and is maintained on
misfolded glycoproteins by UDP–glucose glycoprotein:gluco-
syltransferase [3]. Misfolded, monoglucosylated glycoproteins
are retained within the ER and undergo further folding events.* Corresponding author. Fax: +44-1865-275216.
E-mail address: pauline.rudd@bioch.ox.ac.uk (P.M. Rudd).
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doi:10.1016/j.febslet.2004.04.045a-glucosidase II activity permits secretion by removing the
terminal a1-3-linked glucose (G3); correctly folded glycopro-
teins are not reglucosylated by the glucosyltransferase and
thereby exit the ER and traﬃc to the Golgi for further car-
bohydrate processing [1,3]. Previously, the secretion of glu-
cosylated glycoproteins in human sera has only been observed
in rare pathological states such as glucosidase I deﬁciency
(CDG type IIb) [4].
C3 is a central component of the innate immune system that,
with the other complement proteins, forms a major host
mechanism for the detection and clearance of potential
pathogens [5,6]. C3 is the most abundant complement protein
present in human plasma at 1.0–1.5 mg/ml [7]. Activation of
the complement pathway by, for example, bacteria, results in
the deposition of thousands of activated C3 (C3b) molecules
on the microbe surface. C3b deposition facilitates phagocytosis
by opsonising the target surface. In addition, C3b can associ-
ate with the C3 activating proteases (C3bBb and C4b2a, ac-
tivating the alternative or classical pathway, respectively) to
form the corresponding C5 convertases (C3bBb3b and
C4b2a3b). The C5 convertases catalyse the formation of the
‘Membrane Attack Complex’, C5b-9, which inserts into lipid
bilayers, forming pores that lead to cell lysis. Cell surface
glycoproteins, such as CD46, CD55 and CD59, protect host
cells by negatively regulating the complement cascade.
The majority of complement glycoproteins are synthesised in
the liver [7]. However, plasma C3 has a small contribution
(4.5%) from the kidney [8]. C3 is synthesised as a single
polypeptide chain precursor, which is cleaved before secretion
into a 70-kDa b-chain disulﬁde-linked to a 116-kDa a-chain;
each chain has a single glycosylation site [9]. The structures of
the carbohydrates found on mature secreted proteins are
heavily inﬂuenced by the tissue-speciﬁc expression of glycan
processing enzymes and also the molecular environment of
individual glycosylation sites [2].
In this study, the chemical structures of the N-linked glycan
species on a panel of liver-derived complement components are
presented. Despite sharing a similar biosynthetic pathway, the
glycosylation of C3 diﬀers entirely from the other glycopro-
teins studied. Moreover, we present here the presence of a
population of monoglucosylated glycans on the C3 a-subunit.
This is the ﬁrst report of such structures on mature glyco-
proteins in non-diseased human sera.blished by Elsevier B.V. All rights reserved.
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Fig. 1. NP-HPLC of desialylated 2AB-labelled N -glycans from a panel
of human complement glycoproteins; C2, C3ab, C4, C5a, C8a, C8b,
C9, C4 BP, FB, and FI.
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2.1. Enzymes
Peptide N-glycanase F (PNGase F, EC 3.5.1.52) and exoglycosi-
dase enzymes were obtained from Glyko Inc. (Upper Heyford, UK).
Exoglycosidase digestions were performed as described by Rudd et al.
[10] at the following concentrations with the buﬀers supplied by the
manufacturer: Jack bean a-mannosidase (EC 3.2.1.24), 100 mU/ml;
Arthrobacter ureafaciens sialidase, ABS (EC 3.2.1.18), 1–2 U/ml;
almond meal a-fucosidase (EC 3.2.1.111), 3 mU/ml; bovine testes b-
galactosidase, BTG (EC 3.2.1.23), 1–2 U/ml; Streptococcus pneumo-
niae b-hexosaminidase (EC 3.2.1.30), 120 U/ml; and Aspergillus saitoi
a-mannosidase, ASM (EC 3.2.1.24), 1 mU/ml.
2.2. Puriﬁcation of complement glycoproteins from human sera
Puriﬁcation of complement proteins was performed according to the
following: C3 and C4 [11]; Factor I (FI) [12]; Factor B (FB) [13]; C5
[14]; C4 binding protein (C4 BP) [15]; C2 [16]; C8 [17]; C9 [18].
2.3. Release of N -glycans
In-gel PNGase F digestion of puriﬁed glycoproteins. Oligosaccharides
were puriﬁed for normal phase high-performance liquid chromatog-
raphy (NP-HPLC) analysis from Coomassie-stained SDS–PAGE gels
containing target glycoprotein following PNGase F digestion as de-
scribed by Kuster et al. [19]. Brieﬂy, relevant Coomassie blue-stained
bands containing 10 lg of glycoprotein were excised from reducing
SDS–PAGE gels and washed with 20 mM NaHCO3, pH 7.0. The
washed gel bands were dried in a vacuum centrifuge before rehydration
with 30 ll of 20 mM NaHCO3, pH 7.0, containing 100 U/ml of
PNGase F. After incubation for 12 h at 37 C, the enzymatically re-leased N -glycans were eluted with water extractions. Salts were re-
moved with a 5-min incubation at room temperature with 50 ll of an
acid-activated AG-50W X12 slurry (BioRad, 200–400 mesh), which
was removed by ﬁltration with a 0.45-lm pore-size ﬁlter (Millex-LH,
hydrophobic polytetraﬂuoroethylene).
Release of serum protein N-glycans by hydrazinolysis. Pooled human
serum was dialysed into 0.1% triﬂuoroacetic acid and 50 ll was ly-
ophilized. N -Glycans were released by hydrazinolysis, re-N -acetylated,
and puriﬁed as described by Butler et al. [20].
2.4. Fluorescent labelling and NP-HPLC
The released N -glycan samples were then dried and ﬂuorescently
labelled with 2-aminobenzamide (2AB) by reductive amination [21].
Dried aliquots of 2AB-labelled oligosaccharides were dissolved in a
solution of 20 ll distilled water and 80 ll acetonitrile and analysed by
NP-HPLC using a 4.6 250-mm Glycosep-N column (Glyko Inc.).
The gradient was formed over 152 min with the percentage of solvent
A in acetonitrile rising from 20% to 58% (where solvent A is 50 mM
formic acid, adjusted to pH 4.4 with ammonia). The elution of the
oligosaccharides was measured using a Jasco FP-260 ﬂuorescence de-
tector (Eex ¼ 330 nm, Eem ¼ 420 nm) and calibrated in glucose units
(GU) using a 2AB-labelled dextran hydrolysate. The elution peaks of
each NP-HPLC trace were assigned GU values by comparison with the
calibration ladder and preliminary structural assignments were made
by reference to a database of known standards [22]. Each released N -
glycan pool was subjected to exoglycosidase digestions to further se-
quence the oligosaccharide chains [10,22].3. Results
3.1. Oligosaccharide analysis highlights the glycosylation of C3
Glycan analysis was performed on a panel of complement
glycoproteins known to be synthesised mainly by hepatocytes
[7,8]. Fig. 1 shows a stacked plot of the NP-HPLC traces of re-
leased, desialylated 2AB-labelled N -glycans. Comparison of
these proﬁles shows that C3 is unusual among hepatocyte-de-
rived glycoproteins in containing large oligomannose glycans
(>6 GU).
3.2. C3 contains glucosylated oligomannose glycans
NP-HPLC of the 2AB-labelled glycan pool of whole C3
demonstrated the presence of six glycan species at 6.20, 7.05,
7.95, 8.82, 9.52, and 10.2 GU (Fig. 2). Reference to an ex-
tensive database of glycan standards [10,22], together with GU
values reported in previous studies [23,24], identiﬁed the ﬁrst
ﬁve peaks as the oligomannose series Man5-9GlcNAc2 and the
additional peak at 10.2 GU as the monoglucosylated glycan
Glc1Man9GlcNAc2. Glycan analysis of separated C3a and
C3b subunits revealed that Man8-9GlcNAc2 and the putative
Glc1Man9GlcNAc2 were located on the C3 a subunit, whilst
the C3b subunit contained the smaller Man5-7GlcNAc2 glycans
(Fig. 2).
3.3. Exoglycosidase digestions conﬁrm the presence of
Glc1Man9GlcNAc2 on C3
The entire pool of 2AB-labelled C3 glycans was susceptible
to digestion by Jack bean a-mannosidase but resistant to di-
gestion with sialidase, b-galactosidase, b-hexosaminidase, and
a-fucosidase (data not shown). N-linked oligosaccharides from
the C3a and C3b chains were further analysed by digestion of
the 2AB-labelled glycans with ASM (Fig. 3). This exoglycosi-
dase speciﬁcally hydrolyses terminal a1-2-linked mannoses of
oligomannose structures [24]. However, because the Glca1-
3Man linkage of Glc1Man9GlcNAc2 cannot be hydrolysed by
ASM, the digestion of the D1 and C a1-2 mannose residues of
the capped a1,3 arm is prevented (Fig. 4) [24]. Digestion of the
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Fig. 2. NP-HPLC of 2AB-labelled N -glycans from C3. C3a and C3b
were separated by reductive SDS–PAGE and the N -glycans released
in-gel by PNGase F. The column was calibrated, and GU values
assigned, using a dextran hydrolysate ladder. Man, mannose; N,
GlcNAc.
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Fig. 3. NP-HPLC of 2AB-labelled C3a and C3b N -glycans with and
without digestion with ASM, with GU values. (Ai) Undigested oli-
gosaccharides from C3a; (Aii) and following digestion with ASM. (Bi)
Undigested oligosaccharides from C3b; (Bii) and following digestion
with ASM. G, glucose; Man, mannose; N, GlcNAc.
272 M.D. Max Crispin et al. / FEBS Letters 566 (2004) 270–274C3a glycans with ASM generated two peaks at 6.20 and 8.63
GU (Fig. 3A), whereas the same digest of the C3b glycans
resulted in the generation of a single peak at GU 6.20
(Fig. 3B). The ASM digestion of the C3b glycans hydrolysed
the terminal Mana1-2Man bonds corresponding to the com-
plete digestion of Man6GlcNAc2 and Man7GlcNAc2 to
Man5GlcNAc2, consistent with previous studies which identi-
ﬁed a Man5-7GlcNAc2 series on the C3b subunit [25]. How-
ever, the peak at 10.2 GU in the undigested C3a proﬁle and its
transformation to 8.63 GU following the ASM digest dem-
onstrate the presence of a small population of monoglucosy-
lated N-glycans. The GU transformation of monoglucosylated
glycans following ASM digestion was in agreement with pre-
vious studies [24]. Importantly, the transformation is consis-
tent with the glucose cap being on the D1 arm, as only two
mannose residues were cleaved with ASM [24]. If the glucose
cap was located on either the D2 or D3 arm, then three
mannoses would be released.
3.4. Human sera do not contain detectable levels of
Glc1Man9GlcNAc2
N-linked oligosaccharides were released from pooled human
sera by hydrazinolysis. No neutral glycans were detected over
10 GU, demonstrating that the absolute abundance of
monoglucosylated glycans in human sera is extremely low
(Fig. 5).4. Discussion
In this study, the identiﬁcation of oligomannose N -glycan
structures on both the a- and b-subunits of human C3 is
conﬁrmed and extended to include a population of monoglu-
cosylated N-glycans.
The majority of complement proteins (C1r, C1s, C2, C3, C4,
C5, C6, C8, C9, FB, FH, FI, and C4 BP) are synthesised in the
liver, and a common tissue origin inﬂuences the carbohydrate
structures observed on the mature secreted glycoproteins [2].
However, oligomannose N-glycans were identiﬁed on both C3
and C4, whereas the remaining members of the panel displayed
broadly similar, complex glycans. Since the panel selected was
based on common tissue origin, the most likely explanation for
this variation in glycosylation is the eﬀect of local protein
structure on glycosylation rather than a distinct biosynthetic
mechanism [2]. One caveat is that a small amount (4.5%) of C3
is synthesised in the kidney [8]. However, this small contribu-
tion from a diﬀerent tissue source cannot account for the en-
tirely diﬀerent glycosylation of C3 compared with other
complement glycoproteins.
Secretion of glycoproteins with glucosylated N-glycans has
been reported in disease [4,26] and in non-mammalian systems
[24,27–34]. Recently, Glc1Man9GlcNAc2 was identiﬁed on the
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Fig. 5. NP-HPLC of 2AB-labelled N -glycans from human sera. (A)
Undigested oligosaccharides; (B) following digestion with ABS; (C)
following digestion with ABS and BTG. The grey box highlights the
region where glucosylated Man9GlcNAc2 would be expected.
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Fig. 4. Schematic diagram of Glc1Man9GlcNAc2 and Man9GlcNAc2
and the resulting structures following digestion with ASM.
M.D. Max Crispin et al. / FEBS Letters 566 (2004) 270–274 273acid hydrolase a-mannosidase from Jack bean [32]. This
structure and other oligomannose glycans on a-mannosidase
could only be removed by Endo H under denaturing condi-
tions. Additionally, monoglucosylated N -glycans on the lepi-
dopteran hemolymph arylphorin storage protein could not be
released under native conditions by PNGase F, again sug-
gesting that the protein moiety protects the core of the glycan
from enzymatic cleavage [24].
Buried glycosylation sites have been observed in the crystal
structures of several antibodies [35]. Crystal structures of IgG
Fc reveal that the glycan at Asn-297 is located between the two
adjacent heavy chains and forms many contacts with the
protein surface [36]. Interstitial glycans are present across all
antibody isotypes [35–37], with the notable exception of IgA
[38,39]. The glycans at these interstitial sites exhibit under-
processed glycosylation. For example, the glycans on the Fc of
serum IgA are highly sialylated in contrast to the simpler
neutral glycans of IgG Fc [38]. These structurally buried N-
glycans are generally critical for correct folding and biosyn-
thesis [2]. Interestingly, avian IgY, which is orthologous to
human IgG, has been reported to contain signiﬁcant levels of
Glc1Man9GlcNAc2 [28,29,33,34]. The only previous report
of monoglucosylated N-glycans on a mature human protein of
which the authors are aware is the site-speciﬁc identiﬁcation of
the Glc1Man9GlcNAc2 structure on the IgD:WAH myeloma
protein at the interstitial glycosylation site [26]. Furthermore,
it has recently been shown that the glucosylated structures of
IgY are also located at the interstitial Asn-297 Fc site, where
they remain unavailable for calnexin, calreticulin, or a-gluco-
sidase II interactions [34]. In contrast to the two other glyco-
sylation sites in IgD, only the interstitial glycan is essential for
folding and secretion and is unable to bind concanavalin-A
[40].The calnexin and calreticulin recognition site has been ex-
plored through inhibition studies which demonstrated that the
entire 1,3 arm tetrasaccharide, Glca1-3Mana1-2Mana1-2Man,
forms part of the recognition epitope [41]. The presence of
monoglucosylated N-glycans in secreted glycoproteins suggests
that the sugar is in a region that folds independently of the
calnexin–calreticulin mechanism and renders the a-glucosidase
II cleavage site inaccessible.
The proteolytic state of C3, which changes during the
complement cascade, dramatically inﬂuences the presentation
of a lectin binding site at Asn-917 on the C3 a-subunit [42–44].
The bovine lectin conglutinin binds speciﬁcally with this oli-
gomannose N -glycan on the a-subunit, but can only do so
when C3 has been activated and cleaved (at three sites in the a-
chain) to a form known as iC3b. Conglutinin does not bind C3
or the intermediate product C3b [42–44]. These lectin studies,
together with the identiﬁcation of monoglucosylated N-glycans
on the C3a-subunit reported here, strongly suggest that the N -
glycosylation site at Asn-917 is protected by the protein.5. Conclusions and perspectives
Secretion of glycoproteins bearing the ER retention signal
demonstrates that the calnexin–calreticulin quality control
pathway is not 100% eﬃcient. The secretion of the
274 M.D. Max Crispin et al. / FEBS Letters 566 (2004) 270–274monoglucosylated retention signal is shown here to occur on
complement component C3. Previously, it was reported that a
concealed conglutinin binding site on C3 was revealed upon
conversion to iC3b. Together with the identiﬁcation of secreted
monoglucosylated N-glycans presented here, these data indi-
cate that the glycosylation site on C3a is sterically hidden by
the protein. In conclusion, the presence of monoglucosylated
N-glycans in mature glycoproteins is emerging as a marker of
structurally integral glycosylation sites.
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